ZBTB46

Summary

ZBTB46 (zinc finger and BTB domain containing 46, HGNC:16094) is a protein-coding gene on chromosome 20q13.33, encoding Zinc finger and BTB domain-containing protein 46 (Q86UZ6). Transcription regulator that mediates differentiation of conventional and non-conventional dendritic cells, and which is involved in tolerance to gut microbiota.

Predicted to enable DNA-binding transcription repressor activity, RNA polymerase II-specific and transcription cis-regulatory region binding activity. Involved in regulation of transcription by RNA polymerase II. Predicted to be located in chromatin.

Source: NCBI Gene 140685 — RefSeq curated summary.

At a glance

• GWAS associations: 24
• Clinical variants (ClinVar): 103 total
• MANE Select transcript: NM_001369741

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16094
Approved symbol	ZBTB46
Name	zinc finger and BTB domain containing 46
Location	20q13.33
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13502, RINZF, BZEL
Ensembl gene	ENSG00000130584
Ensembl biotype	protein_coding
OMIM	614639
Entrez	140685

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 11 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000245663, ENST00000395104, ENST00000460757, ENST00000480766, ENST00000650966, ENST00000906793, ENST00000906794, ENST00000906795, ENST00000906796, ENST00000912108, ENST00000912109, ENST00000947317, ENST00000947318, ENST00000947319

RefSeq mRNA: 2 — MANE Select: NM_001369741 NM_001369741, NM_025224

CCDS: CCDS13538

Canonical transcript exons

ENST00000245663 — 5 exons

Exon	Start	End
ENSE00000856639	63743670	63747301
ENSE00001172488	63752686	63752861
ENSE00001172501	63789821	63790790
ENSE00001451279	63831097	63831264
ENSE00003635371	63775678	63775962

Expression profiles

Bgee: expression breadth ubiquitous, 215 present calls, max score 90.72.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.2863 / max 46.9928, expressed in 951 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
188416	2.2863	951

Top tissues by expression

240 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oviduct epithelium	UBERON:0004804	90.72	gold quality
tendon of biceps brachii	UBERON:0008188	89.69	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.71	gold quality
cerebellar hemisphere	UBERON:0002245	87.48	gold quality
cerebellar cortex	UBERON:0002129	87.40	gold quality
cerebellum	UBERON:0002037	87.04	gold quality
cartilage tissue	UBERON:0002418	86.88	gold quality
visceral pleura	UBERON:0002401	85.60	gold quality
sural nerve	UBERON:0015488	84.82	gold quality
epithelial cell of pancreas	CL:0000083	83.91	silver quality
tibia	UBERON:0000979	83.88	gold quality
apex of heart	UBERON:0002098	83.41	gold quality
spleen	UBERON:0002106	82.75	gold quality
parietal pleura	UBERON:0002400	82.45	gold quality
germinal epithelium of ovary	UBERON:0001304	81.79	gold quality
right ovary	UBERON:0002118	81.28	gold quality
left ovary	UBERON:0002119	81.02	gold quality
ovary	UBERON:0000992	80.91	gold quality
heart left ventricle	UBERON:0002084	80.69	gold quality
right lobe of thyroid gland	UBERON:0001119	80.36	gold quality
cardiac ventricle	UBERON:0002082	80.35	gold quality
corpus epididymis	UBERON:0004359	80.18	gold quality
adenohypophysis	UBERON:0002196	79.98	gold quality
Brodmann (1909) area 23	UBERON:0013554	79.76	gold quality
pancreatic ductal cell	CL:0002079	79.50	silver quality
left lobe of thyroid gland	UBERON:0001120	79.18	gold quality
middle temporal gyrus	UBERON:0002771	79.18	gold quality
metanephros	UBERON:0000081	79.17	gold quality
left uterine tube	UBERON:0001303	78.87	gold quality
thyroid gland	UBERON:0002046	78.81	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6142	no	3.61
E-ANND-3	no	3.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

137 targeting ZBTB46, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580

Literature-anchored findings (GeneRIF, showing 8)

• A single nucleotide polymorphisn in ZBTB46, rs6062314, is associated with an increased genetic risk for multiple sclerosis. (PMID:23739915)
• Authors report a novel tumor promoter, ZBTB46, which is negatively regulated by AR signaling via microRNA (miR)-1-mediated downregulation. ZBTB46 is associated with malignant prostate cancer and is essential for metastasis. (PMID:28692046)
• ZBTB46 is able to clearly define the dendritic cell identity of many previously unclassified histiocytic disease subtypes. All examined cases of Langerhans cell histiocytosis and histiocytic sarcoma expressed ZBTB46, while all cases of blastic plasmacytoid dendritic cell neoplasm, chronic myelomonocytic leukemia, juvenile xanthogranuloma, Rosai-Dorfman disease, and Erdheim-Chester disease failed to express ZBTB46. (PMID:29743654)
• In vitro results using endothelial cells (ECs) showed that cell confluence and laminar shear stress, both known physiological conditions promoting EC quiescence, led to upregulation of ZBTB46 expression. (PMID:29884909)
• ZBTB46 is inversely correlated with SPDEF and is increased in higher tumor grades and small-cell NE prostate cancer (SCNC) patients, which are positively associated with PTGS1. Findings suggest that the induction of ZBTB46 results in increased PTGS1 expression, which is associated with NEPC progression and linked to the dysregulation of the AR-SPDEF pathway. (PMID:30312731)
• Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. (PMID:33398073)
• Single nucleotide variations in ZBTB46 are associated with post-thrombolytic parenchymal haematoma. (PMID:33723576)
• PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer. (PMID:34815524)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	zbtb46	ENSDARG00000078191
mus_musculus	Zbtb46	ENSMUSG00000027583
rattus_norvegicus	Zbtb46	ENSRNOG00000014592

Paralogs (28): ZNF280C (ENSG00000056277), ZBTB25 (ENSG00000089775), PRDM13 (ENSG00000112238), BCL6 (ENSG00000113916), FEZF1 (ENSG00000128610), PRDM12 (ENSG00000130711), ZNF280D (ENSG00000137871), NACC2 (ENSG00000148411), FEZF2 (ENSG00000153266), ZBTB7B (ENSG00000160685), NACC1 (ENSG00000160877), BCL6B (ENSG00000161940), GFI1 (ENSG00000162676), GFI1B (ENSG00000165702), ZBTB49 (ENSG00000168826), ZNF280A (ENSG00000169548), ZNF581 (ENSG00000171425), ZNF524 (ENSG00000171443), ZBTB26 (ENSG00000171448), ZBTB21 (ENSG00000173276), ZNF683 (ENSG00000176083), ZBTB33 (ENSG00000177485), ZBTB3 (ENSG00000185670), ZBTB6 (ENSG00000186130), ZBTB14 (ENSG00000198081), ZBTB12 (ENSG00000204366), ZNF580 (ENSG00000213015), ZNF280B (ENSG00000275004)

Protein

Protein identifiers

Zinc finger and BTB domain-containing protein 46 — Q86UZ6 (reviewed: Q86UZ6)

Alternative names: BTB/POZ domain-containing protein 4, Zinc finger protein 340

All UniProt accessions (2): Q86UZ6, A0A494BZW5

UniProt curated annotations — full annotation on UniProt →

Function. Transcription regulator that mediates differentiation of conventional and non-conventional dendritic cells, and which is involved in tolerance to gut microbiota. Together with RORgammaT (RORC), specifically expressed in type 3 innate lymphoid cells (ILC3s) that are required for tolerance to gut microbiota, to mediate differentiation of peripherally-induced regulatory T-cells (pTreg), which suppress inflammatory responses to commensal microorganisms. Functions as a transcription corepressor for PRDM1.

Subcellular location. Nucleus. Chromosome.

Post-translational modifications. Sumoylated. Desumoylation by DESI1 reverses transcriptional repression activity.

RefSeq proteins (2): NP_001356670, NP_079500 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050457	ZnFinger_BTB_dom_contain	Family

Pfam: PF00651, PF13465

UniProt features (12 total): compositionally biased region 3, zinc finger region 2, region of interest 2, chain 1, domain 1, cross-link 1, sequence variant 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86UZ6-F1	55.56	0.09

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 229, 234

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 148 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_DENDRITIC_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, GOBP_TOLERANCE_INDUCTION, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_REGULATION_OF_DENDRITIC_CELL_DIFFERENTIATION, TGCACTT_MIR519C_MIR519B_MIR519A, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MYELOID_LEUKOCYTE_DIFFERENTIATION, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GOBP_ORGAN_OR_TISSUE_SPECIFIC_IMMUNE_RESPONSE

GO Biological Process (14): negative regulation of transcription by RNA polymerase II (GO:0000122), plasmacytoid dendritic cell differentiation (GO:0002273), tolerance induction in gut-associated lymphoid tissue (GO:0002394), negative regulation of leukocyte activation (GO:0002695), regulation of transcription by RNA polymerase II (GO:0006357), macrophage differentiation (GO:0030225), granulocyte differentiation (GO:0030851), negative regulation of granulocyte differentiation (GO:0030853), regulatory T cell differentiation (GO:0045066), negative regulation of macrophage differentiation (GO:0045650), negative regulation of monocyte differentiation (GO:0045656), negative regulation of dendritic cell differentiation (GO:2001199), positive regulation of dendritic cell differentiation (GO:2001200), dendritic cell differentiation (GO:0097028)

GO Molecular Function (7): transcription cis-regulatory region binding (GO:0000976), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), transcription coregulator activity (GO:0003712), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
dendritic cell differentiation	3
negative regulation of myeloid leukocyte differentiation	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
myeloid leukocyte differentiation	2
mononuclear cell differentiation	2
regulation of dendritic cell differentiation	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
negative regulation of DNA-templated transcription	1
plasmacytoid dendritic cell activation	1
immune response in gut-associated lymphoid tissue	1
tolerance induction in mucosal-associated lymphoid tissue	1
negative regulation of immune system process	1
regulation of leukocyte activation	1
leukocyte activation	1
negative regulation of cell activation	1
regulation of DNA-templated transcription	1
granulocyte differentiation	1
regulation of granulocyte differentiation	1
T cell differentiation	1
macrophage differentiation	1
regulation of macrophage differentiation	1
monocyte differentiation	1
regulation of monocyte differentiation	1
negative regulation of leukocyte differentiation	1
positive regulation of leukocyte differentiation	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
transcription regulator activity	1
transition metal ion binding	1
binding	1
cation binding	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

946 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZBTB46	BATF3	Q9NR55	712
ZBTB46	XCR1	P46094	712
ZBTB46	MPPE1	Q53F39	644
ZBTB46	ITGAE	P38570	620
ZBTB46	ITGAX	P20702	620
ZBTB46	IRF8	Q02556	614
ZBTB46	FLT3	P36888	608
ZBTB46	IRF4	Q15306	583
ZBTB46	CLEC9A	Q6UXN8	582
ZBTB46	ITGAM	P11215	570
ZBTB46	FCGR1A	P12314	517
ZBTB46	CCR7	P32248	516
ZBTB46	FLT3LG	P49771	507
ZBTB46	SIRPA	P78324	507
ZBTB46	SMIM24	O75264	490

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CUL1	LGALS8	psi-mi:“MI:0914”(association)	0.350
ZBTB46	SNRNP200	psi-mi:“MI:0914”(association)	0.350
ZBTB46	AP2A2	psi-mi:“MI:0914”(association)	0.350

BioGRID (59): EHMT1 (Affinity Capture-MS), PRPF8 (Affinity Capture-MS), GATAD2B (Affinity Capture-MS), GATAD2A (Affinity Capture-MS), MBD3 (Affinity Capture-MS), MTA1 (Affinity Capture-MS), AP2A1 (Affinity Capture-MS), AP2A2 (Affinity Capture-MS), RGPD5 (Affinity Capture-MS), DDX23 (Affinity Capture-MS), ZBTB10 (Affinity Capture-MS), EHMT2 (Affinity Capture-MS), FBXL17 (Affinity Capture-MS), BTRC (Affinity Capture-MS), FBXW11 (Affinity Capture-MS)

ESM2 similar proteins: A0JN76, A1L2U9, B1WAZ8, B1WBU4, O15060, O35260, O43298, O93567, P14404, P41182, P41183, Q05516, Q0IH98, Q0IJ29, Q0P4X6, Q0V8G8, Q0VCJ6, Q15916, Q1L8W0, Q3B725, Q3SWU4, Q5TC79, Q5ZM39, Q6NRM8, Q6P882, Q6YND2, Q7TQG0, Q7TSZ8, Q7ZWZ4, Q801P1, Q80X44, Q86UZ6, Q8BID6, Q8CII0, Q8K088, Q8K0L9, Q8N680, Q8NAP8, Q8NCN2, Q8NCP5

Diamond homologs: A0JN76, A1L2U9, A1YEX3, A1YPR0, A2AAX3, B1WAZ8, B1WBS3, B1WBU4, B2RXF5, D3ZA50, O14867, O15062, O15156, O15209, O43167, O43298, O43829, O88282, O88939, O93567, O95365, P24278, P41182, P41183, P52739, P97302, P97303, Q08376, Q0IH98, Q0IJ29, Q0P4X6, Q0VCJ6, Q13105, Q14526, Q1H9T6, Q1L8W0, Q2T9Z7, Q3B725, Q3B7N9, Q3SWU4

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
ZBTB46	“up-regulates quantity by expression”	PCK1	“transcriptional regulation”
ZBTB46	“up-regulates quantity by expression”	LIF	“transcriptional regulation”
AR	“down-regulates quantity by repression”	ZBTB46	“transcriptional regulation”
ZBTB46	up-regulates	“Neuroendocrine cell differentiation”
ZBTB46	“up-regulates quantity by expression”	PTGS1	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

103 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	93
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2606 predictions. Top by Δscore:

Variant	Effect	Δscore
20:63752682:TCACC:T	donor_loss	1.0000
20:63752683:CA:C	donor_loss	1.0000
20:63752684:A:AC	donor_gain	1.0000
20:63752685:C:CC	donor_gain	1.0000
20:63752685:CCAG:C	donor_gain	1.0000
20:63752857:ATTCA:A	acceptor_gain	1.0000
20:63752858:TTCA:T	acceptor_gain	1.0000
20:63752859:TCA:T	acceptor_gain	1.0000
20:63752860:CA:C	acceptor_gain	1.0000
20:63752860:CAC:C	acceptor_gain	1.0000
20:63752861:AC:A	acceptor_loss	1.0000
20:63752862:C:CC	acceptor_gain	1.0000
20:63752862:CTGAA:C	acceptor_loss	1.0000
20:63752863:T:A	acceptor_loss	1.0000
20:63775676:A:AC	donor_gain	1.0000
20:63775677:C:CC	donor_gain	1.0000
20:63775677:CGGGA:C	donor_gain	1.0000
20:63775960:CAT:C	acceptor_gain	1.0000
20:63775963:C:CC	acceptor_gain	1.0000
20:63783515:T:A	donor_gain	1.0000
20:63790789:CT:C	acceptor_gain	1.0000
20:63831091:GCTTA:G	donor_loss	1.0000
20:63831092:CTTA:C	donor_loss	1.0000
20:63831093:TTA:T	donor_loss	1.0000
20:63831094:TA:T	donor_loss	1.0000
20:63831095:ACC:A	donor_loss	1.0000
20:63831096:C:CT	donor_loss	1.0000
20:63746994:T:TA	donor_gain	0.9900
20:63752679:CACT:C	donor_loss	0.9900
20:63752680:ACTC:A	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000021453 (20:63816729 T>C), RS1000050635 (20:63827851 A>G), RS1000060675 (20:63750934 A>C), RS1000078560 (20:63831471 G>A,C), RS1000088133 (20:63818184 G>A), RS1000130539 (20:63752168 C>T), RS1000140913 (20:63765248 G>A), RS1000146367 (20:63796825 CA>C,CAA), RS1000171247 (20:63797517 C>T), RS1000246629 (20:63797141 A>G), RS1000267801 (20:63768308 T>A), RS1000277065 (20:63765425 T>C,G), RS1000317945 (20:63833418 C>T), RS1000324298 (20:63745646 G>A), RS1000341311 (20:63827561 T>C)

Disease associations

OMIM: gene MIM:614639 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

24 associations (top):

Study	Trait	p-value
GCST000964_24	Ulcerative colitis	2.000000e-10
GCST001198_86	Multiple sclerosis	1.000000e-07
GCST001762_811	Obesity-related traits	4.000000e-06
GCST001942_22	Prostate cancer	4.000000e-16
GCST004131_34	Inflammatory bowel disease	3.000000e-26
GCST004132_110	Crohn’s disease	3.000000e-13
GCST004133_15	Ulcerative colitis	9.000000e-17
GCST005194_66	Coronary artery disease	2.000000e-06
GCST007563_15	Allergic disease (asthma, hay fever or eczema)	3.000000e-08
GCST007564_6	Asthma or allergic disease (pleiotropy)	3.000000e-10
GCST007930_100	Medication use (agents acting on the renin-angiotensin system)	4.000000e-17
GCST008362_127	Birth weight	2.000000e-11
GCST008723_7	Marginal zone lymphoma or multiple sclerosis	2.000000e-08
GCST008916_69	Asthma	3.000000e-09
GCST009380_9	Type 2 diabetes (adjusted for BMI)	6.000000e-06
GCST009640_57	Urinary albumin-to-creatinine ratio	2.000000e-08
GCST009856_14	Leukocyte telomere length	6.000000e-12
GCST009856_21	Leukocyte telomere length	3.000000e-10
GCST010132_3	Processed meat consumption	1.000000e-09
GCST010143_12	Meat-related diet	7.000000e-09
GCST010266_17	Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass	8.000000e-07
GCST010267_6	Trunk fat mass adjusted for trunk lean mass	2.000000e-07
GCST90000047_267	Age at first sexual intercourse	1.000000e-09
GCST90002392_119	Mean corpuscular volume	3.000000e-10

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004458	C-reactive protein measurement
EFO:0009931	Agents acting on the renin-angiotensin system use measurement
EFO:0004344	birth weight
EFO:0007778	urinary albumin to creatinine ratio
EFO:0008111	diet measurement
EFO:0007785	femoral neck bone mineral density
EFO:0009749	age at first sexual intercourse measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression, increases expression	3
Valproic Acid	increases expression, increases methylation	3
sodium arsenite	increases abundance, increases expression	2
Arsenic	affects methylation, increases abundance, increases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation	2
dicrotophos	decreases expression	1
arsenite	increases methylation	1
benzo(e)pyrene	increases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Decitabine	affects expression	1
Vorinostat	decreases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Cisplatin	affects expression	1
Coumestrol	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Ethyl Methanesulfonate	increases expression	1
Lead	decreases expression	1
Methapyrilene	increases methylation	1
Niclosamide	increases expression	1
Phthalic Acids	increases methylation	1
Polychlorinated Biphenyls	affects expression	1
Silicon Dioxide	decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	decreases methylation	1
Tretinoin	decreases expression	1
Aflatoxin B1	increases methylation	1
Acrylamide	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.